Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
76.84
-0.16 (-0.21%)
Official Closing Price
Updated: 7:00 PM EDT, Jul 1, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
10,899,581
Open
76.98
Bid (Size)
75.50 (1)
Ask (Size)
79.00 (2)
Prev. Close
77.00
Today's Range
75.77 - 76.98
52wk Range
53.22 - 80.59
Shares Outstanding
2,222,113,553
Dividend Yield
2.55%
Intraday
1 Week
1 Month
3 Month
1 Year
Top News
More News
Hot Stocks: Tickers Moved By Traders on 'Fast Money: Halftime Report'
July 01, 2022
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors.
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
July 01, 2022
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.
Via
Benzinga
Performance
YTD
+24.18%
+24.18%
1 Month
+2.51%
+2.51%
3 Month
+4.09%
+4.09%
6 Month
+23.24%
+23.24%
1 Year
+15.44%
+15.44%
More News
Read More
This Is What Whales Are Betting On Bristol-Myers Squibb
June 30, 2022
Via
Benzinga
The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data
June 29, 2022
Via
Benzinga
5 S&P 500 Stocks Ready to Break Out
June 29, 2022
Via
InvestorPlace
Looking Into Bristol-Myers Squibb's Recent Short Interest
June 29, 2022
Via
Benzinga
New York Judge Denies Bristol Myers Claim To Dismiss Lawsuit Over Delayed Cancer Drug Approval: Reuters
June 27, 2022
Via
Benzinga
UnitedHealth, Shockwave Lead 5 Healthy Stocks Breaking Out Or Setting Up
June 25, 2022
Via
Investor's Business Daily
U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
June 24, 2022
From
Bristol Myers Squibb
Via
Business Wire
This Is What Whales Are Betting On Bristol-Myers Squibb
June 24, 2022
Via
Benzinga
Bristol Myers Squibb Presents New Data Showing Effect of Early Zeposia (ozanimod) Treatment in Improving and Preserving Cognitive Function in People With Relapsing Multiple Sclerosis
June 24, 2022
From
Bristol Myers Squibb
Via
Business Wire
New Data Highlight Immune Response to COVID-19 Vaccines in Individuals with Relapsing Forms of Multiple Sclerosis Treated with Zeposia (ozanimod)
June 24, 2022
From
Bristol Myers Squibb
Via
Business Wire
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial
June 24, 2022
Via
Benzinga
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
June 20, 2022
From
Bristol Myers Squibb
Via
Business Wire
The 5 Top Profit & Protection Stocks to Buy for 2022
June 17, 2022
Via
InvestorPlace
Bristol Myers Squibb Announces Dividend
June 15, 2022
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
June 15, 2022
From
Bristol Myers Squibb
Via
Business Wire
Cisco And 2 Other Stocks Insiders Are Selling
June 15, 2022
Via
Benzinga
As Health Problems Mount Patients Welcome New Treatments
June 14, 2022
Via
FinancialNewsMedia
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
June 13, 2022
Via
Benzinga
Looking At Bristol-Myers Squibb's Recent Whale Trades
June 10, 2022
Via
Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
June 10, 2022
Via
Benzinga
7 Blue-Chip Stocks With Strong Dividend Yields
June 09, 2022
Via
InvestorPlace
SELLAS Life Sciences's Galinpepimut/Opdivo Combo Shows Increased Survival In Mesothelioma Patients
June 08, 2022
Via
Benzinga
Bristol Myers Squibb to Report Results for Second Quarter 2022 on July 27, 2022
June 08, 2022
From
Bristol Myers Squibb
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.